Literature DB >> 21606474

Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation.

Bhushan Kumar, Tarun Narang.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21606474     DOI： 10.1136/sextrans-2011-050025

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN： 1368-4973            Impact factor:   3.519


× No keyword cloud information.
  8 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream.

Authors:  Na Hee Kim; Jee Bum Lee; Sook Jung Yun
Journal:  Ann Dermatol       Date:  2018-06-28       Impact factor: 1.444

3.  An Investigator-initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses on Dorsal Hands and Forearms.

Authors:  Gary Goldenberg; Rita V Linkner; Giselle Singer; Amylynne Frankel
Journal:  J Clin Aesthet Dermatol       Date:  2013-02

4.  The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation.

Authors:  Louis Nerurkar; Alison McColl; Gerard Graham; Jonathan Cavanagh
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

5.  CO(2) Laser therapy versus cryotherapy in treatment of genital warts; a Randomized Controlled Trial (RCT).

Authors:  M Azizjalali; Gh Ghaffarpour; B Mousavifard
Journal:  Iran J Microbiol       Date:  2012-12

6.  High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery.

Authors:  Dhara A Patel; Anand C Patel; William C Nolan; Yong Zhang; Michael J Holtzman
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

7.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

Review 8.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.